Patent intelligence · WO
WO 2025106633
INHIBITEURS DE TYK2
INHIBITEURS DE TYK2
Patent details — WO 2025106633
- Jurisdiction
- WO
- Status
- granted
- Grant date
- May 22, 2025
- Expiration
- May 17, 2045
- Applicant
- BIOGEN MA INC [US]
- CPC classes
- A61K 31/ 407 A I, A61K/31407, A61P 31/ 18 A I, A61P 35/ 00 A I
Quick answer
WO 2025106633 (INHIBITEURS DE TYK2) is held by BIOGEN MA INC [US]. Status: granted. Granted May 22, 2025. Expires May 17, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- BIOGEN MA INC [US]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 31/ 407 A I, A61K/31407, A61P 31/ 18 A I, A61P 35/ 00 A I, A61P/3118, A61P/3500
More from BIOGEN MA INC [US]
Related pharmaceutical patents in our USPTO index.
-
WO 2026112397
COMPOSITIONS ET PROCÉDÉS DE PRODUCTION DE VIRUS ADÉNO-ASSOCIÉS
granted -
WO 2026085433
PROCÉDÉS POUR PRÉPARER DES CONJUGUÉS OLIGONUCLÉOTIDIQUES
granted -
WO 2026060131
ADDITIFS POUR LA PRODUCTION DE VECTEURS VIRAUX
granted -
WO 2026055127
PROCÉDÉ DE PRODUCTION D'UN MODULATEUR DE RÉCEPTEUR GABA
granted -
WO 2026044005
PARTICULES DE VAA COMPRENANT DES PEPTIDES CONTENANT RGD POUR ADMINISTRER DES CHARGES UTILES DE DYSTROPHINE
granted -
WO 2026025082
MÉTHODES DE TRAITEMENT DE LA MALADIE D'ALZHEIMER
granted -
WO 2025207932
CAPSIDES DE VAA COMPRENANT DES DOMAINES D'ANTICORPS ANTI-TRANSFERRINE
granted -
WO 2025207959
ANTICORPS ANTI-RÉCEPTEURS DE LA TRANSFERRINE ET LEURS UTILISATIONS
granted
Frequently asked questions
What is US patent 2025106633?
WO 2025106633 (INHIBITEURS DE TYK2) is held by BIOGEN MA INC [US]. Status: granted. Granted May 22, 2025. Expires May 17, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns WO 2025106633?
BIOGEN MA INC [US] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.
When does WO 2025106633 expire?
Our index shows an expiration date of May 17, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.